Canada Life’s Aclaris Therapeutics ACRS Stock Holding History

Canada Life’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,944	Closed	-$2K	–	2140
2023 Q4	$2K	Hold	1,944	–	–	﹤0.01%	2158
2023 Q3	$13K	Hold	1,944	–	–	﹤0.01%	2186
2023 Q2	$20K	Hold	1,944	–	–	﹤0.01%	2142
2023 Q1	$16K	Hold	1,944	–	–	﹤0.01%	2241
2022 Q4	$31K	Hold	1,944	–	–	﹤0.01%	2169
2022 Q3	$31K	Hold	1,944	–	–	﹤0.01%	2178
2022 Q2	$27K	Hold	1,944	–	–	﹤0.01%	2200
2022 Q1	$36K	Hold	1,944	–	–	﹤0.01%	2233
2021 Q4	$28K	Hold	1,944	–	–	﹤0.01%	2308
2021 Q3	$35K	Hold	1,944	–	–	﹤0.01%	2320
2021 Q2	$34K	Buy	+1,944	New	+$44.2K	﹤0.01%	2370
2019 Q2	–	Sell	-6,072	Closed	-$36K	–	2774
2019 Q1	$36K	Hold	6,072	–	–	﹤0.01%	2311
2018 Q4	$43K	Buy	+6,072	New	+$62.6K	﹤0.01%	2422
2018 Q1	–	Sell	-5,242	Closed	-$129K	–	2711
2017 Q4	$129K	Buy	5,242 +4,042	+337%	+$98.4K	﹤0.01%	2099
2017 Q3	$31K	Hold	1,200	–	–	﹤0.01%	2429
2017 Q2	$32K	Hold	1,200	–	–	﹤0.01%	2430
2017 Q1	$36K	Hold	1,200	–	–	﹤0.01%	2377
2016 Q4	$33K	Hold	1,200	–	–	﹤0.01%	2412
2016 Q3	$31K	Hold	1,200	–	–	﹤0.01%	2421
2016 Q2	$22K	Buy	+1,200	New	+$23.8K	﹤0.01%	2456

Other funds holding ACRS

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Canada Life's ACRS Position: Q1 2024 in Review

Canada Life sold out of Aclaris Therapeutics (ACRS) in Q1 2024, closing a stake of 1,944 shares — an estimated $2K sold.

Canada Life first reported a position in ACRS in Q2 2016 and held it in 20 quarters. The position peaked at $129K in Q4 2017. 98 funds tracked by Wall St. Rank hold ACRS as of Q1 2024.

Canada Life reported no remaining Aclaris Therapeutics position as of Q1 2024 after selling out during the quarter.
Canada Life sold 1,944 Aclaris Therapeutics shares in Q1 2024, an estimated $2K.
Canada Life first reported a position in Aclaris Therapeutics in Q2 2016 and held it in 20 quarters.
Canada Life's Aclaris Therapeutics position peaked at $129K in Q4 2017.
98 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2024.

Based on Canada Life's 13F filing for Q1 2024, filed 13 May 2024.